Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.

NCT ID: NCT02919059

Last Updated: 2017-03-29

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 159 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-12-13
• Study Completion Date: 2019-08-31

Brief Summary

This superiority of central pressure versus peripheral measures to predict cardiovascular events has also been reported in general population or in elder people

Detailed Description

The prognostic value of central systolic/diastolic pressure, central pulse pressure and AI has been well demonstrated, firstly after CAFÉ study, with 2073 hypertensive subjects followed up 3.4 years. It also evidenced higher prognostic value of central blood pressure compared to peripheral blood pressure. One year later, the STRONG study, showed central pulse pressure to be an independent cardiovascular risk factor as well as higher prognostic value compared to peripheral pulse pressure (Hazard ratio; 1,1510 mmHg Vs 1,10mmHg; X2: 13,4; p < 0,001). Those subjects with higher central blood pressure and central pulse pressure showed higher incidence of cardiovascular events. This superiority of central pressure versus peripheral measures to predict cardiovascular events has also been reported in general population or in elder people.

Finally, it has been also reported that dapagliflozin modestly reduces systolic blood pressure in patients with T2DM who were mostly receiving treatment for hypertension. Despite office blood pressure remains the gold standard method for screening, diagnostic and treatment of hypertension, it has been also well demonstrated that ambulatory blood pressure monitoring (ABPM) better estimates cardiovascular risk and target organ damage than office blood pressure. It still remains unclear the effects on 24 hours blood pressure reduction with SGLT-2 inhibitors.

The effects of SGLT2 inhibitors on central blood pressure reduction have not been documented.

Conditions

Diabetes Mellitus, Type 2

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Dapagliflozin 10 mg

Dapagliflozin 10 mg once daily during 24 weeks

Group Type: EXPERIMENTAL

Dapagliflozin 10 mg

Intervention Type: DRUG

Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.

On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.

The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal.

Glimepiride 4 mg

Glimepiride 4 mg once daily during 24 weeks

Group Type: ACTIVE_COMPARATOR

Glimepiride 4 mg

Intervention Type: DRUG

Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.

On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.

The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal.

Interventions

Dapagliflozin 10 mg

Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.

On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.

The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal.

Intervention Type: DRUG

Glimepiride 4 mg

Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.

On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.

The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal.

Intervention Type: DRUG

Other Intervention Names

Dapagliflozin; Glimepiride

Eligibility Criteria

Inclusion Criteria

• T2DM subjects with uncontrolled glycaemia, based on HbA1c levels (10% ≥ HbA1c ≥ 7%) at Visit 1.
• Patients may be treated for >3 months with a stable doses of metformin at optimal doses tolerated.
• Participants will be able to give and sign informed consent form.
• Age > 18 years of either gender.

Exclusion Criteria

• Patients with two or more different oral antihyperglycemic agents.
• HbA 1c levels > 10%.
• Systolic BP >160 mm Hg and/or diastolic BP > 100 mm Hg before randomization.
• History of diabetic ketoacidosis, T1DM, pancreas or beta-cell transplantation or diabetes secondary to any condition.
• History of one or more severe hypoglycaemic episode within 6 months before screening.
• Myocardial infarction, unstable angina pectoris, congestive heart failure, life threatening arrhythmia, history of cerebrovascular accident within 3 months.
• Clinically relevant renal disease; defines if serum creatinine equal or lager than 1.5 mg/dl or eGFR < 60 ml/min/1.73m2, at screening.
• Liver function abnormal: glutamic-oxalacetic transaminase lager than 2 times of upper limit normal or glutamic-pyruvic transaminase lager than 2 times of upper limit normal
• Existence of any serious systemic disease
• Allergic history to the compounds of study medication
• Can not comply the study protocol or misunderstand the informed consent form
• Women of childbearing potential will be required to use a double-barrier method of birth control throughout study participation. Women who are surgically sterile or documented post-menopausal for at least 2 years are not considered to be of childbearing potential.
• Pregnant or breast-feeding or planning to become pregnant during the study.
• History of alcohol abuse (>350 g/week) within 3 years before screening.
• Concurrent therapy with medications that could be affect glycaemia (e.g. corticosteroids) or disallowed therapy (e.g. digoxin).
• Investigational drug treatment within the past 4 months
• Concomitant psychiatric diseases and/or habit/abuse of psychoactive substances
• Predictable lack of co-operation
• Shifts workers
• Employees of the investigator or study centre.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

IInstituto Gallego de Medicina Vascular

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Alvaro Hermida, MD, PhD

Role: STUDY_DIRECTOR

Hospital Nuestra Señora de la Esperanza

Locations

Hospital Nuestra Señora de la Esperanza

Santiago de Compostela, Galicia, Spain

Site Status: RECRUITING

Countries

Spain

Central Contacts

Alvaro Hermida, MD, PhD

Role: CONTACT

alvaro.hermida.ameijeiras@sergas.es

0034 981 552 200

Facility Contacts

Álvaro Hermida, MD, PhD

Role: primary

alvaro.hermida.ameijeiras@sergas.es

0034 981 552 200

Other Identifiers

ESR-14-10158

Identifier Type: -

Identifier Source: org_study_id